Assessing Adherence to Antihypertensive Therapy in Primary Health Care in Namibia: Findings and Implications

Cardiovascular Drugs and Therapy

Volumn 31, Issue 5-6, 2017, Pages 565-578

  Nashilongo, M M ^a   Singu, B ^a   Kalemeera, F ^a   Mubita, M ^a   Naikaku, E ^a   Baker, A ^b   Ferrario, A ^c   Godman, B ^b,d,e   Achieng, L ^f   Kibuule, D ^a  

^a UNIVERSITY OF NAMIBIA   (Namibia)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^f UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

Adherence; Hypertension; Namibia; Primary health care; Universal access

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASSESSMENT OF HUMANS; CONSTRUCT VALIDITY; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; FAMILY; FEMALE; FOLLOW UP; HILL BONE COMPLIANCE SCALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAMIBIA; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RELIABILITY; SUBURBAN AREA; SUPPORT GROUP; MEDICATION COMPLIANCE; ORGANIZATION AND MANAGEMENT; PRINCIPAL COMPONENT ANALYSIS; STANDARDS; STATISTICS AND NUMERICAL DATA;

ANTIHYPERTENSIVE AGENTS; CROSS-SECTIONAL STUDIES; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; NAMIBIA; PRIMARY HEALTH CARE; PRINCIPAL COMPONENT ANALYSIS;

EID: 85031427999     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-017-6756-8     Document Type: Article

References (51)

1. World Health Organisation (WHO). A global brief on hypertension—silent killer, global public health crisis. World Health Day 2013. Available at URL: http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf?ua=1
2. Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne AP. Burden of undiagnosed hypertension in Sub-Saharan Africa: a systematic review and meta-analysis. Hypertension. 2015;65(2):291–8.
3. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513–8.
4. Irazola VE, Gutierrez L, Bloomfield G, Carrillo-Larco RM, Dorairaj P, Gaziano T, et al. Hypertension prevalence, awareness, treatment, and control in selected low and middle income countries (LMIC) communities: results from the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases. Glob Heart. 2016;11(1):47–59.
5. World Health Organisation, Global Health Observatory (GHO) data. Raised blood pressure. Available at URL: http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/
6. Nielsen JO, Shrestha AD, Neupane D, Kallestrup P. Non-adherence to anti-hypertensive medication in low- and middle-income countries: a systematic review and meta-analysis of 92443 subjects. J Hum Hypertens. 2017;31(1):14–21.
7. Hendriks ME, Wit FWNM, Roos MTL, Brewster LM, Akande TM, de Beer IH, et al. Hypertension in Sub-Saharan Africa: cross-sectional surveys in four rural and urban communities. PLoS One. 2012;7(3):e32638.
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.
9. World Health Organisation. Namibia: World Health Organisation statistical profile. Available at URL: http://www.who.int/gho/countries/nam.pdf?ua=1
10. The Nambia Ministry of Health and Social Services (MoHSS) and ICF International. 2014. The Namibia Demographic and Health Survey 2013. Windhoek, Namibia, and Rockville, Maryland, USA: MoHSS and ICF International. Available at URL: https://dhsprogram.com/pubs/pdf/FR298/FR298.pdf.
11. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29(3):610–8.
12. World Health Organisation. Millennium developmet goals sustainable development goals Chapter 6. Noncommunicable diseases. Available at URL: http://www.who.int/gho/publications/mdgs-sdgs/MDGs-SDGs2015_chapter6.pdf?ua=1
13. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19(4):357–62.
14. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403–19.
15. Mant J, McManus RJ. Does it matter whether patients take their antihypertensive medication as prescribed? The complex relationship between adherence and blood pressure control. J Hum Hypertens. 2006;20(8):551–3.
16. Ministry of Health and Social Services. Namibia essential medicines list [Nemlist] 5th edition. Republic of Namibia Ministry of Health and Social Services, Windhoek, Namibia. Available at URL: http://apps.who.int/medicinedocs/documents/s23017en/s23017en.pdf
17. Ministry of Health and Social Services. Namibia Standard treatment guidelines 1st edition. Republic of Namibia Ministry of Health and Social Services Windhoek Namibia. Available at URL: http://apps.who.int/medicinedocs/documents/s19260en/s19260en.pdf
18. Ministry of Health and Social Services. National medicines policy 2nd edition. Republic of Namibia Ministry of Health and Social Services, Windhoek, Namibia. 2011.
19. Ministry of Health and Social Services. Republic of Namibia. Medicines and related substances control Act, 13, Republic of Namibia, 2003. Available at URL: http://www.wipo.int/edocs/lexdocs/laws/en/na/na017en.pdf
20. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373(9659):240–9.
21. Bell R, Ithindi T, Low A. Improving equity in the provision of primary health care: lessons from decentralized planning and management in Namibia. Bull World Health Organ. 2002;80(8):675–81.
22. Mweene D, Banda J, Andrews B, M-Mweene M, Lakhi S. Factors associated with poor medication adherence in hypertensive patients in Lusaka, Zambia. Med J Zambia. 2010;37(3):252–61.
23. WHO. How to investigate drug use in health facilities: selected drug use Indicators—EDM Research Series No. 007. Available at URL: http://apps.who.int/medicinedocs/en/d/Js2289e/
24. Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the hill-bone compliance to high blood pressure therapy scale. Prog Cardiovasc Nurs. 2000;15(3):90–6.
25. Sarker SK, Bt Kamal NAI, Bin Rohazaki AA, Rashid AFBZ, Bt Mansor F, Halim NBA, et al. Prevalence of patients compliance among hypertensive patients and its associated factors in Klinik Kesihatan Botanic Klang, Malaysia. Int J Intg Med Sci. 2016;3(7):345–9.
26. Dehghan M, Nayeri ND, Iranmanesh S. Validating the Persian version of the Hill-Bone’s scale of “compliance to high blood pressure therapy”. Br J Med Med Res. 2015;5(2):235–46.
27. Lambert EV, Steyn K, Stender S, Everage N, Fourie JM, Hill M. Cross-cultural validation of the hill-bone compliance to high blood pressure therapy scale in a South African, primary healthcare setting. Ethn Dis. 2006;16:286–91.
28. Culig J, Leppee M. From Morisky to Hill-bone; self-reports scales for measuring adherence to medication. Coll Antropol. 2014;38(1):55–62.
29. Berra E, Azizi M, Capron A, Hoieggen A, Rabbia F, Kjeldsen SE, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68(2):297–306.
30. Inkster ME, Donnan PT, MacDonald TM, Sullivan FM, Fahey T. Adherence to antihypertensive medication and association with patient and practice factors. J Hum Hypertens. 2006;20(4):295–7.
31. Karademir M, Koseoglu IH, Vatansever K, Van Den Akker M. Validity and reliability of the Turkish version of the Hill-Bone compliance to high blood pressure therapy scale for use in primary health care settings. Eur J Gen Pract. 2009;15(4):207–11.
32. Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc. 2011;51(1):90–4.
33. Song Y, Han HR, Song HJ, Nam S, Nguyen T, Kim MT. Psychometric evaluation of hill-bone medication adherence subscale. Asian Nurs Res. 2011;5(3):183–8.
34. Uchmanowicz I, Jankowska-Polańska B, Chudiak A, Szymańska-Chabowska A, Mazur G. Psychometric evaluation of the polish adaptation of the hill-bone compliance to high blood pressure therapy scale. BMC Cardiovasc Disord. 2016;16:87.
35. Mafutha GN, Wright SC. Compliance or non-compliance of hypertensive adults to hypertension management at three primary healthcare day clinics in Tshwane. Curationis. 2013;36(1):E1–6.
36. Acheing L, Joshi M, Ogola EN, Karari E. Adequacy of blood pressure control and level of adherence with antihypertensive therapy. East Afr Med J. 2009;86(11):499–506.
37. Demoner MS, Ramos ERDP, Pereira ER. Factors associated with adherence to antihypertensive treatment in a primary care unit. Acta Paulista de Enfermagem. 2012;25(Special Issue 1):27–34.
38. Awad EY, Gwaied BE, Fouda LM, Essa HAE-GE. Compliance of hypertensive patients with treatment regimen and its effect on their quality of life. J Nurs Health Sci. 2015;4(2):26–36.
39. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ. 1995;311(7000):293–5.
40. Ma C. A cross-sectional survey of medication adherence and associated factors for rural patients with hypertension. Appl Nurs Res. 2016;31:94–9.
41. Ambaw AD, Alemie GA, W/Yohannes SM, Mengesha ZB. Adherence to antihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. BMC Public Health. 2012;12:282.
42. Coleman R, Gill G, Wilkinson D. Noncommunicable disease management in resource-poor settings: a primary care model from rural South Africa. Bull World Health Organ. 1998;76(6):633–40.
43. Erhun WO, Agbani EO, Bolaji EE. Positive benefits of a pharmacist-managed hypertension clinic in Nigeria. Public Health. 2005;119(9):792–8.
44. Saounatsou M, Patsi O, Fasoi G, Stylianou M, Kavga A, Economou O, et al. The influence of the hypertensive patient’s education in compliance with their medication. Public Health Nurs. 2001;18(6):436–42.
45. Yiannakopoulou E, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil. 2005;12(3):243–9.
46. Mugwano I, Kaddumukasa M, Mugenyi L, Kayima J, Ddumba E, Sajatovic M, et al. Poor drug adherence and lack of awareness of hypertension among hypertensive stroke patients in Kampala, Uganda: a cross sectional study. BMC research notes. 2016;9:3.
47. Adams AS, Uratsu C, Dyer W, Magid D, O’Connor P, Beck A, et al. Health system factors and antihypertensive adherence in a diverse cohort of new users. JAMA Intern Med. 2013;173(1):54–61.
48. Akeroyd JM, Chan WJ, Kamal AK, Palaniappan L, Virani SS. Adherence to cardiovascular medications in the South Asian population: a systematic review of current evidence and future directions. World J Cardiol. 2015;7(12):938–47.
49. Harmon G, Lefante J, Krousel-Wood M. Overcoming barriers: the role of providers in improving patient adherence to antihypertensive medications. Curr Opin Cardiol. 2006;21(4):310–5.
50. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 European Society of Hypertension/European Society of Cardiology(ESH/ESC) guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension. J Hypertens. 2013;31(7):1281–357.
51. Rwegerera G, Moshomo T, Gaenamong M, Oyewo TA, Gollakota S, Mhimbira FA, et al. Antidiabetic medication adherence and associated factors among patients in Botswana; implications for the future. Alex J Med. 2017; https://doi.org/10.1016/j.ajme.2017.01.005.